HUTCHMED China Limited (HCM)

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02...

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”...

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary...

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

Form 3 - Initial statement of beneficial ownership of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]